Study on the efficacy of lenvatinib combined with Huachansu in the treatment of advanced hepatocellular carcinoma

DOI: 10.12201/bmr.202604.00069

•  

  Abstract: Objective:To study the specific effect of the combination therapy of lenvatinib and Huachansu in the treatment of advanced hepatocellular carcinoma.Methods:A retrospective analysis of clinical data from 62 patients with mid-to-late stage hepatocellular carcinoma admitted to The 900th Hospital of the PLA Joint Logistic Support Force (hereinafter referred to as The 900th Hospital) between January 2023 and August 2025. Based on different treatment regimens, the patients were divided into a control group (treated with lenvatinib monotherapy) and a study group (treated with lenvatinib combined with huachansu), each comprising 31 cases. Compare the short-term efficacy, incidence of adverse reactions, and changes in tumor markers, hematological parameters, and liver function indicators before and after treatment between the two patient groups.Results:Disease control rates were significantly higher in the study group compared to the control group (P<0.05); The overall incidence of adverse reactions showed no statistically significant difference between the two groups (P>0.05); After treatment, levels of alpha-fetoprotein (AFP), protein induced by vitamin k absence or antagonist-Ⅱ (PIVKA-II), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels decreased compared to pre-treatment levels in both groups, with the study group showing lower levels than the control group (P<0.05).Conclusion:The combination therapy of lenvatinib and huachansu more effectively improves disease control rates in patients with advanced hepatocellular carcinoma, reduces tumor marker levels, enhances prognosis and liver function, while not increasing adverse reactions.

  Key words: Lenvatinib; Huachansu; Advanced hepatocellular carcinoma; Drug resistance; Liver function

  Submit time: 9 April 2026

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• Xu Chen. Diagnostic value of ACR CEUS LI-RADS for hepatocellular carcinoma in high-risk and non-high-risk populations. 2026. doi: 10.12201/bmr.202601.00041

  LU Ming, ZHONG Peisong, REN Honglei, YIN Fanglan. Recent Advances in Precision-Based Early Screening for Hepatocellular Carcinoma. 2025. doi: 10.12201/bmr.202512.00013

  Wang Ya-jing, Peng Pei, Zhang Xue. Exploration of the Pathogenic characteristics of Hepatocellular Carcinoma Liver Depression and Spleen Deficiency Based on the. 2025. doi: 10.12201/bmr.202506.00030

  Zheyi Fang, Wenjun Zhu, Jiayan Huang. A Bibliometric Analysis on Global Research Activities of Antimicrobial Resistance. 2022. doi: 10.12201/bmr.202207.00021

  HU Wei,. Clinical Efficacy of Penpulimab Combined Chemotherapy in Non-Squamous NSCLC. 2025. doi: 10.12201/bmr.202508.00045

  ChenYu, libowen, yangjinhua, liuyang, weiyunwei. Research progress and prospect of targeted therapy of microflora in hepatocellular carcinoma. 2024. doi: 10.12201/bmr.202412.00033

  jinmin, jinmin. Research Progress on Traditional Chinese Medicines for Reversing Bacterial Resistance and Their Mechanisms of Action. 2025. doi: 10.12201/bmr.202503.00056

  quyanli. Efficacy and safety of preoperative chemotherapy in real world patients with locally advanced gastric/gastroesophageal junction adenocarcinoma. 2024. doi: 10.12201/bmr.202409.00052

  胡芷晴, Pan Shan, Zhu Weili. Advances in Research on Ferroptosis Reversing Platinum Resistance in Ovarian Cancer. 2025. doi: 10.12201/bmr.202512.00070

  邓锐. . 2025. doi: 10.12201/bmr.202510.00062

• ID	Submit time	Number	Download
  1	2026-03-23	10.12201/bmr.202604.00069V1	Download

• Public  Anonymous  To author only Submit Comments